These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 30233304)

  • 1. Circulating miRNAs as Diagnostic Biomarkers for Parkinson's Disease.
    Roser AE; Caldi Gomes L; Schünemann J; Maass F; Lingor P
    Front Neurosci; 2018; 12():625. PubMed ID: 30233304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Exosomal miRNA as Diagnostic Biomarkers of Neurodegenerative Diseases.
    Wang L; Zhang L
    Front Mol Neurosci; 2020; 13():53. PubMed ID: 32351363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA Dysregulation in Parkinson's Disease: A Narrative Review.
    Nies YH; Mohamad Najib NH; Lim WL; Kamaruzzaman MA; Yahaya MF; Teoh SL
    Front Neurosci; 2021; 15():660379. PubMed ID: 33994934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.
    Leggio L; Vivarelli S; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Marchetti B; Iraci N
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comprehensive Study of miRNAs in Parkinson's Disease: Diagnostics and Therapeutic Approaches.
    Owais S; Siddique YH
    CNS Neurol Disord Drug Targets; 2023; 22(3):353-380. PubMed ID: 35021980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-Synuclein as a Biomarker for Parkinson's Disease.
    Atik A; Stewart T; Zhang J
    Brain Pathol; 2016 May; 26(3):410-8. PubMed ID: 26940058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease?
    O'Hara DM; Pawar G; Kalia SK; Kalia LV
    Front Neurosci; 2020; 14():577. PubMed ID: 32625052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian.
    Mo M; Xiao Y; Huang S; Cen L; Chen X; Zhang L; Luo Q; Li S; Yang X; Lin X; Xu P
    Oncotarget; 2017 Jan; 8(1):15-28. PubMed ID: 27965467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. microRNAs: Emerging Targets Regulating Oxidative Stress in the Models of Parkinson's Disease.
    Xie Y; Chen Y
    Front Neurosci; 2016; 10():298. PubMed ID: 27445669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model.
    Kong Y; Liang X; Liu L; Zhang D; Wan C; Gan Z; Yuan L
    PLoS One; 2015; 10(9):e0137432. PubMed ID: 26361355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
    Miraglia F; Betti L; Palego L; Giannaccini G
    Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease.
    Grosch J; Winkler J; Kohl Z
    Front Cell Neurosci; 2016; 10():293. PubMed ID: 28066188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease and microRNAs - Lessons from model organisms and human studies.
    Evans B; Furlong HA; de Lencastre A
    Exp Gerontol; 2021 Nov; 155():111585. PubMed ID: 34634413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease.
    Pavlou MAS; Pinho R; Paiva I; Outeiro TF
    Brain; 2017 Apr; 140(4):878-886. PubMed ID: 27585855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating MicroRNAs and Long Non-coding RNAs as Potential Diagnostic Biomarkers for Parkinson's Disease.
    Yang Y; Li Y; Yang H; Guo J; Li N
    Front Mol Neurosci; 2021; 14():631553. PubMed ID: 33762908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.
    Teixeira Dos Santos MC; Bell R; da Costa AN
    Bioanalysis; 2016 Dec; 8(23):2497-2518. PubMed ID: 27855513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.